Evidence map›Paper›PMID 37966015›Full record

Observational studyTherapeutic advances in respiratory disease

Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study.

Laurent Guilleminault, Claire Camus, Chantal Raherison-Semjen, Audrey Capdepon, Arnaud Bourdin, Philippe Bonniaud, Stéphanie Fry, Gilles Devouassoux, François-Xavier Blanc, Christophe Pison and 25 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Exploring trends and predictors of long-term asthma remission.The World Allergy Organization journal · 2025
    Article
  3. Article
  4. Allergen Immunotherapy for the Prevention and Treatment of Asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 17 institutions in 2 countries.

Laurent GuilleminaultDepartment of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France.ORCID 0000-0002-7344-8290
Claire CamusCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Chantal Raherison-SemjenCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Audrey CapdeponAstraZeneca, Paris, France.
Arnaud BourdinCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Philippe BonniaudCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Stéphanie FryCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Gilles DevouassouxCRISALIS/F-CRIN INSERM Network, Toulouse, France.
François-Xavier BlancCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Christophe PisonCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Clairelyne DupinCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Naji KhayathCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Joelle CourdeauRespiratory Diseases Department, Bigorre Hospital, Tarbes, France.
Judith Valcke-BrossolletPrivate practice in Armand Brillard Hospital, Nogent-sur-Marne, France.
Cécilia Nocent-EjnainiRespiratory Diseases Department, Côte-Basque Hospital, Bayonne, France.
Fabien RollandRespiratory Diseases Department, Cannes Hospital, Cannes, France.
Carmen LamandiRespiratory Diseases Department, GHRMSA Hospital, Mulhouse, France.
Alain ProustRespiratory Diseases Department, Nimes Hospital, Nîmes, France.
Anaig OzierRespiratory Diseases Department, Saint Augustin Clinic, Bordeaux, France.
Laurent PortelRespiratory Diseases Department, Libourne Hospital, Libourne, France.
Wanda GaspardRespiratory Diseases Department, Army Training Hospital HIA Percy Clamart, Clamart, France.
Pauline Roux-ClaudeCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Antoine BeurnierCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Stéphanie MartinezRespiratory Diseases Department, Aix-en-Provence Hospital, Aix-en-Provence, France.
Jean-Marc DotRespiratory Diseases Department, Médipôle Hospital, Villeurbanne, France.
Florence HennegraveRespiratory Diseases Department, Dunkerque Hospital, Dunkerque, France.
Guillaume VignalRespiratory Diseases Department, Pau Hospital, Pau, France.
Etienne AuvrayRespiratory Diseases Department, Métropole Savoie Hospital, Chambéry, France.
Nicolas PaleironRespiratory Diseases Department, Army Training Hospital HIA Ste Anne Toulon, Toulon, France.
Nicolas JustRespiratory Diseases Department, Roubaix Hospital, Roubaix, France.
Jean MiltgenRespiratory Diseases Department, Polyclinique Les Fleurs, Ollioules, France.
Maud RussierRespiratory Diseases Department, Orléans Regional Hospital, Orléans, France.
Cécile OlivierRespiratory Diseases Department, La Louvière Private Hospital, Lille, France.
Camille TailléCRISALIS/F-CRIN INSERM Network, Toulouse, France.
Alain DidierDepartment of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France.
Inserm · FRCentre National de la Recherche Scientifique · FRAstraZeneca (France) · FRCentre Hospitalier de Bigorre · FRCentre Hospitalier de Cannes · FRCentre Hospitalier de la Côte Basque · FRCentre Hospitalier De Pau · FRCentre Hospitalier de Roubaix · FRCentre Hospitalier du Pays d'Aix · FRCentre Hospitalier Métropole Savoie · FRCentre hospitalier universitaire d'Orléans · FRGroupe Hospitalier de la Région de Mulhouse et Sud Alsace · FRHôpital d'instruction des Armées Percy · FRHôpital d'Instruction des Armées Sainte-Anne · FRHôpital Pellegrin · FRMédipole Garonne · FRSaint Laurent Polyclinique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. PURPOSE: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics.

designThe

methodsAdults with a confirmed diagnosis of severe asthma for at least 12 months' duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders.

resultsThe characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma.

conclusionAlthough a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.

Indexed as

Anti-Asthmatic AgentsAsthmaBiological ProductsGastroesophageal RefluxSleep Apnea, ObstructiveAdultHumansInflammationQuality of LifeAnti-Asthmatic AgentsBiological Productsbiologicshealthcareoral corticosteroidquality of lifesevere asthma

Identifiers

PMID37966015
PMCPMC10655663
OpenAlexW4388699593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.